Ken Griffin Aligos Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,400 shares of ALGS stock, worth $13,398. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,400
Previous 3,800
63.16%
Holding current value
$13,398
Previous $3,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ALGS
# of Institutions
45Shares Held
47.2MCall Options Held
1.4KPut Options Held
300-
Armistice Capital, LLC New York, NY7.26MShares$69.4 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$61.1 Million0.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$58.4 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5MShares$47.9 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$33.9 Million0.18% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $380M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...